NEW YORK (GenomeWeb News) – InforSense said today that it has struck agreements with two UK research institutes who will use its translational research tools to develop diagnostic tools for mental health and in Alzheimer’s disease studies.
InforSense said that the National Institute of Health Research’s Biomedical Research Center for Mental Health, and the Maudsley National Health Service Foundation Trust and Institute of Psychiatry, Kings College London, will use its InforSense solution to help access, handle, and visualize data from biomarker research.
The company’s translational research solution includes the InforSense platform, Clinical Sense, GenSense, BioSense, and the VisualSense Portal.
Scientists at the Biomedical Research Center for Mental Health will use the platform to integrate and analyze patient, genotyping, transcriptomics, proteomics, and MRI data in pursuit of biomarkers.
The company said that the InforSense platform will enable researchers and clinicians to access their entire patient and ‘omics data through a common interface, and that it will help them eliminate errors associated with manual data handling and bottlenecks to data access.
Financial terms of the agreements were not released.